Featured Research

from universities, journals, and other organizations

Scientists discover how HIV virus gains access to carrier immune cells to spread infection

Date:
December 18, 2012
Source:
Public Library of Science
Summary:
Scientists have identified how HIV, the virus that causes AIDS, enters the cells of the immune system enabling it to be dispersed throughout an organism.

Scientists from the AIDS Research Institute IrsiCaixa have identified how HIV, the virus that causes AIDS, enters the cells of the immune system enabling it to be dispersed throughout an organism. The new study is published December 18 in the open access journal PLOS Biology.

One of the reasons why we do not yet have a cure for HIV infection is that the virus infects cells of the immune system that would normally fight such an infection. The main targets of HIV are white blood cells named CD4 T lymphocytes (so called because they have the protein CD4 in their membrane), and while more than 20 different drugs are available today to help control HIV, all of them act by blocking the cycle that HIV follows to infect these CD4 T lymphocytes. However, these treatments do not fully act on another cell of the immune system, the dendritic cell, which takes up HIV and spreads it to target CD4 T lymphocytes.

Mature dendritic cells are responsible for activating an immune response by CD4 T lymphocytes, but when they carry viruses, their contact with T lymphocytes causes the virus to be passed on, thus increasing viral spread.

The results continue the research led by ICREA researchers at IrsiCaixa, Javier Martínez-Picado, and Nuria Izquierdo-Useros, in collaboration with research groups from Heidelberg University, Germany, and the University of Lausanne, Switzerland. This team published a previous PLOS Biology paper in April 2012, in which they identified molecules, called gangliosides, located on the surface of HIV that are recognized by dendritic cells and are necessary for viral uptake. The new results now identify a molecule on the surface of dendritic cells that recognizes and binds the gangliosides and allows HIV to be taken up by dendritic cells and transmitted to its ultimate target: T lymphocytes.

"We have observed that the protein that acts as a lock for the entrance of HIV could also facilitate the entrance of other viruses," explains Nuria Izquierdo-Useros. "Therefore, our results could also help us understand how other infections might exploit this mechanism of dispersion."

In order to identify the precise molecule located on the membrane of the dendritic cells capable of capturing HIV, the researchers studied one family of proteins that are present on the surface of these cells, called Siglecs. It is known that these proteins bind to the gangliosides on the HIV surface. In the laboratory, they mixed the virus with dendritic cells that displayed different quantities of Siglec-1, and found that a higher quantity of Siglec-1 led to those dendritic cells capturing more HIV, which in turn allowed for enhanced transmission of HIV to CD4 T lymphocytes, a process called trans-infection.

The team then tried inhibiting the Siglec-1 protein. Doing so in the laboratory, they found that the dendritic cells lost their capacity to capture HIV and, importantly, they also lost their ability to transfer HIV to CD4 T lymphocytes. With all these data, the scientists concluded that Siglec-1 is the molecule responsible for HIV entrance into the dendritic cells, and could therefore become a new therapeutic target.

"We had the key and now we have found a lock," explains Javier Martínez-Picado. "Now we are already working on the development of a drug that could block this process to improve the efficacy of the current existing treatments against AIDS."


Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Journal Reference:

  1. Nuria Izquierdo-Useros, Maier Lorizate, Maria C. Puertas, Maria T. Rodriguez-Plata, Nadine Zangger, Elina Erikson, Maria Pino, Itziar Erkizia, Bärbel Glass, Bonaventura Clotet, Oliver T. Keppler, Amalio Telenti, Hans-Georg Kräusslich, Javier Martinez-Picado. Siglec-1 Is a Novel Dendritic Cell Receptor That Mediates HIV-1 Trans-Infection Through Recognition of Viral Membrane Gangliosides. PLoS Biology, 2012; 10 (12): e1001448 DOI: 10.1371/journal.pbio.1001448

Cite This Page:

Public Library of Science. "Scientists discover how HIV virus gains access to carrier immune cells to spread infection." ScienceDaily. ScienceDaily, 18 December 2012. <www.sciencedaily.com/releases/2012/12/121218203506.htm>.
Public Library of Science. (2012, December 18). Scientists discover how HIV virus gains access to carrier immune cells to spread infection. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2012/12/121218203506.htm
Public Library of Science. "Scientists discover how HIV virus gains access to carrier immune cells to spread infection." ScienceDaily. www.sciencedaily.com/releases/2012/12/121218203506.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) — The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) — The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) — The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) — In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins